fashion -WSS

fashion

author：focus 2025-09-28 02:33:16 - browse：28388

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： FDA's Woodcock to retire early next year

WSS

Congress must reauthorize a committee to support older Americans

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Childhood cancer progress stalls for Black, Hispanic kids: Report

In key trial, Verve's treatment lowers cholesterol levels in patients

PBMs drew scrutiny in House hearing — and so did pharma

In key trial, Verve's treatment lowers cholesterol levels in patients

Wikipedia

fashion

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Free Covid tests will again be offered to all U.S. households

How one medical school became remarkably diverse

Senate bill would ban some hospital facility fees

Continuity nursing helped my family in our darkest PICU moments

PBM reforms clear House panel

Bright Health sells Medicare Advantage business to Molina

Chamber of Commerce, DOJ clash in court over drug prices

In age of alternative facts, a scholarly course on calling out crap

How the messy conversation about Dolly changed bioethics

leisure time

The struggle to figure out which patients 'deserve' Wegovy

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Congress must reauthorize a committee to support older Americans

White House Covid adviser calls on docs to combat misinformation

Neurocrine congenital adrenal hyperplasia trial succeeds

The unintended consequences of overturning Roe v. Wade

focus

explore

Wikipedia

hotspot